Literature DB >> 24596158

Diaphragm dysfunction in heart failure is accompanied by increases in neutral sphingomyelinase activity and ceramide content.

Hyacinth M Empinado1, Gergana M Deevska, Mariana Nikolova-Karakashian, Jeung-Ki Yoo, Demetra D Christou, Leonardo F Ferreira.   

Abstract

AIMS: Chronic heart failure (CHF) causes inspiratory (diaphragm) muscle weakness and fatigue that contributes to dyspnoea and limited physical capacity in patients. However, the mechanisms that lead to diaphragm dysfunction in CHF remain poorly understood. Cytokines and angiotensin II are elevated in CHF and stimulate the activity of the enzyme sphingomyelinase (SMase) and accumulation of its reaction product ceramide. In the diaphragm, SMase or ceramide exposure in vitro causes weakness and fatigue. Thus, elevated SMase activity and ceramide content have been proposed as mediators of diaphragm dysfunction in CHF. In the present study, we tested the hypotheses that diaphragm dysfunction was accompanied by increases in diaphragm SMase activity and ceramide content. METHODS AND
RESULTS: Myocardial infarction was used to induce CHF in rats. We measured diaphragm isometric force, SMase activity by high-performance liquid chromatography, and ceramide subspecies and total ceramide using mass spectrometry. Diaphragm force was depressed and fatigue accelerated by CHF. Diaphragm neutral SMase activity was increased by 20% in CHF, while acid SMase activity was unchanged. We also found that CHF increased the content of C18 -, C20 -, and C24 -ceramide subspecies and total ceramide. Downstream of ceramide degradation, diaphragm sphingosine was unchanged, and sphingosine-1-phosphate level was increased in CHF.
CONCLUSION: Our major novel finding was that diaphragm dysfunction in CHF rats was accompanied by higher diaphragm neutral SMase activity, which is expected to cause the observed increase in diaphragm ceramide content.
© 2014 The Authors. European Journal of Heart Failure © 2014 European Society of Cardiology.

Entities:  

Keywords:  Dyspnoea; Force; Myocardial infarction; Skeletal muscle; Sphingolipids

Mesh:

Substances:

Year:  2014        PMID: 24596158      PMCID: PMC4655596          DOI: 10.1002/ejhf.73

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  36 in total

1.  Sphingosine 1-phosphate signaling is involved in skeletal muscle regeneration.

Authors:  Daniela Danieli-Betto; Samantha Peron; Elena Germinario; Marika Zanin; Guglielmo Sorci; Susanna Franzoso; Dorianna Sandonà; Romeo Betto
Journal:  Am J Physiol Cell Physiol       Date:  2009-12-30       Impact factor: 4.249

2.  Neutral sphingomyelinase 2 (smpd3) in the control of postnatal growth and development.

Authors:  Wilhelm Stoffel; Britta Jenke; Barbara Blöck; Markus Zumbansen; Jürgen Koebke
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-11       Impact factor: 11.205

3.  Secretory sphingomyelinase is upregulated in chronic heart failure: a second messenger system of immune activation relates to body composition, muscular functional capacity, and peripheral blood flow.

Authors:  Wolfram Doehner; Alexander C Bunck; Mathias Rauchhaus; Stephan von Haehling; Frank M Brunkhorst; Mariantonietta Cicoira; Carsten Tschope; Piotr Ponikowski; Ralf A Claus; Stefan D Anker
Journal:  Eur Heart J       Date:  2007-03-12       Impact factor: 29.983

4.  Exercise training in chronic heart failure: correlation between reduced local inflammation and improved oxidative capacity in the skeletal muscle.

Authors:  Stephan Gielen; Volker Adams; Axel Linke; Sandra Erbs; Sven Möbius-Winkler; Andreas Schubert; Gerhard Schuler; Rainer Hambrecht
Journal:  Eur J Cardiovasc Prev Rehabil       Date:  2005-08

5.  Diaphragmatic free radical generation increases in an animal model of heart failure.

Authors:  Gerald S Supinski; Leigh A Callahan
Journal:  J Appl Physiol (1985)       Date:  2005-09

6.  Inspiratory muscle training in patients with heart failure and inspiratory muscle weakness: a randomized trial.

Authors:  Pedro Dall'Ago; Gaspar R S Chiappa; Henrique Guths; Ricardo Stein; Jorge P Ribeiro
Journal:  J Am Coll Cardiol       Date:  2006-01-26       Impact factor: 24.094

7.  Neutral sphingomyelinase inhibition participates to the benefits of N-acetylcysteine treatment in post-myocardial infarction failing heart rats.

Authors:  Christophe Adamy; Paul Mulder; Lara Khouzami; Nathalie Andrieu-abadie; Nicole Defer; Gabriele Candiani; Catherine Pavoine; Philippe Caramelle; Richard Souktani; Philippe Le Corvoisier; Magali Perier; Matthias Kirsch; Thibaud Damy; Alain Berdeaux; Thierry Levade; Christian Thuillez; Luc Hittinger; Françoise Pecker
Journal:  J Mol Cell Cardiol       Date:  2007-06-30       Impact factor: 5.000

8.  Impaired isotonic contractility and structural abnormalities in the diaphragm of congestive heart failure rats.

Authors:  Hieronymus W H van Hees; Henricus F M van der Heijden; Theo Hafmans; Leo Ennen; Leo M A Heunks; Freek W A Verheugt; P N Richard Dekhuijzen
Journal:  Int J Cardiol       Date:  2007-08-08       Impact factor: 4.164

9.  Diaphragm single-fiber weakness and loss of myosin in congestive heart failure rats.

Authors:  Hieronymus W H van Hees; Henricus F M van der Heijden; Coen A C Ottenheijm; Leo M A Heunks; Cindy J C Pigmans; Freek W A Verheugt; Rene M H J Brouwer; P N Richard Dekhuijzen
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-04-20       Impact factor: 4.733

10.  Exercise training prevents TNF-α induced loss of force in the diaphragm of mice.

Authors:  Norman Mangner; Axel Linke; Andreas Oberbach; Yvonne Kullnick; Stephan Gielen; Marcus Sandri; Robert Hoellriegel; Yasuharu Matsumoto; Gerhard Schuler; Volker Adams
Journal:  PLoS One       Date:  2013-01-02       Impact factor: 3.240

View more
  19 in total

1.  The novel cardiac myosin activator omecamtiv mecarbil increases the calcium sensitivity of force production in isolated cardiomyocytes and skeletal muscle fibres of the rat.

Authors:  L Nagy; Á Kovács; B Bódi; E T Pásztor; G Á Fülöp; A Tóth; I Édes; Z Papp
Journal:  Br J Pharmacol       Date:  2015-08-04       Impact factor: 8.739

2.  Diaphragm weakness and proteomics (global and redox) modifications in heart failure with reduced ejection fraction in rats.

Authors:  Rachel C Kelley; Brian McDonagh; Babette Brumback; Glenn A Walter; Ravneet Vohra; Leonardo F Ferreira
Journal:  J Mol Cell Cardiol       Date:  2020-02-05       Impact factor: 5.000

3.  Diaphragm dysfunction caused by sphingomyelinase requires the p47(phox) subunit of NADPH oxidase.

Authors:  Elaina R Bost; Gregory S Frye; Bumsoo Ahn; Leonardo F Ferreira
Journal:  Respir Physiol Neurobiol       Date:  2014-10-24       Impact factor: 1.931

4.  Diaphragm muscle weakness in mice is early-onset post-myocardial infarction and associated with elevated protein oxidation.

Authors:  T Scott Bowen; Norman Mangner; Sarah Werner; Stefanie Glaser; Yvonne Kullnick; Andrea Schrepper; Torsten Doenst; Andreas Oberbach; Axel Linke; Leif Steil; Gerhard Schuler; Volker Adams
Journal:  J Appl Physiol (1985)       Date:  2014-10-30

5.  NAD(P)H oxidase subunit p47phox is elevated, and p47phox knockout prevents diaphragm contractile dysfunction in heart failure.

Authors:  Bumsoo Ahn; Adam W Beharry; Gregory S Frye; Andrew R Judge; Leonardo F Ferreira
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-07-24       Impact factor: 5.464

6.  Small-hairpin RNA and pharmacological targeting of neutral sphingomyelinase prevent diaphragm weakness in rats with heart failure and reduced ejection fraction.

Authors:  Philip D Coblentz; Bumsoo Ahn; Linda F Hayward; Jeung-Ki Yoo; Demetra D Christou; Leonardo F Ferreira
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-01-31       Impact factor: 5.464

Review 7.  Insulin Signaling and Heart Failure.

Authors:  Christian Riehle; E Dale Abel
Journal:  Circ Res       Date:  2016-04-01       Impact factor: 17.367

Review 8.  Diaphragm abnormalities in heart failure and aging: mechanisms and integration of cardiovascular and respiratory pathophysiology.

Authors:  Rachel C Kelley; Leonardo F Ferreira
Journal:  Heart Fail Rev       Date:  2017-03       Impact factor: 4.214

9.  Pharmacological targeting of mitochondrial reactive oxygen species counteracts diaphragm weakness in chronic heart failure.

Authors:  Orlando Laitano; Bumsoo Ahn; Nikhil Patel; Philip D Coblentz; Ashley J Smuder; Jeung-Ki Yoo; Demetra D Christou; Peter J Adhihetty; Leonardo F Ferreira
Journal:  J Appl Physiol (1985)       Date:  2016-02-04

10.  Sphingomyelinase promotes oxidant production and skeletal muscle contractile dysfunction through activation of NADPH oxidase.

Authors:  James A Loehr; Reem Abo-Zahrah; Rituraj Pal; George G Rodney
Journal:  Front Physiol       Date:  2015-01-21       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.